Ci Investments Inc. Legend Biotech Corp Transaction History

Ci Investments Inc.

$26.3 Billion
Q3 2024

A detailed history of Ci Investments Inc. transactions in Legend Biotech Corp stock. As of the latest transaction made, Ci Investments Inc. holds 6,348 shares of LEGN stock, worth $216,339. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,348

Previous 6,686 5.06%

Holding current value

$216,339

Previous $296,000 4.39%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$43.55 - $59.88 $14,719 - $20,239	-338 Reduced 5.06%	6,348 $309,000
Q2 2024 Aug 12, 2024	BUY	$39.5 - $57.22 $46,531 - $67,405	1,178 Added 21.39%	6,686 $296,000
Q1 2024 May 13, 2024	BUY	$55.06 - $69.99 $99,548 - $126,541	1,808 Added 48.86%	5,508 $309,000
Q4 2023 Feb 12, 2024	SELL	$57.25 - $69.74 $28,052 - $34,172	-490 Reduced 11.69%	3,700 $223,000
Q3 2023 Nov 13, 2023	SELL	$63.16 - $76.5 $40,043 - $48,501	-634 Reduced 13.14%	4,190 $281,000
Q2 2023 Aug 11, 2023	BUY	$46.28 - $75.01 $52,018 - $84,311	1,124 Added 30.38%	4,824 $333,000
Q1 2023 May 12, 2023	BUY	$43.42 - $57.37 $53,710 - $70,966	1,237 Added 50.22%	3,700 $178,000
Q4 2022 Feb 10, 2023	BUY	$38.8 - $55.46 $84,700 - $121,069	2,183 Added 779.64%	2,463 $123,000
Q3 2022 Nov 14, 2022	SELL	$38.15 - $57.1 $267 - $399	-7 Reduced 2.44%	280 $11,000
Q2 2022 Aug 12, 2022	SELL	$33.54 - $55.0 $14,656 - $24,035	-437 Reduced 60.36%	287 $16,000
Q1 2022 May 12, 2022	SELL	$31.02 - $48.18 $1,302 - $2,023	-42 Reduced 5.48%	724 $26,000
Q4 2021 Feb 11, 2022	BUY	$41.14 - $56.98 $31,513 - $43,646	766 New	766 $36,000

Others Institutions Holding LEGN

# of Institutions

225

Shares Held

74.3M

Call Options Held

279K

Put Options Held

350K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $5.71B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ci Investments Inc. with notifications on news.

Account

Ci Investments Inc. Legend Biotech Corp Transaction History